{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:07:32Z","timestamp":1767154052008,"version":"build-2238731810"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 105-2633-B-009-003"],"award-info":[{"award-number":["MOST 105-2633-B-009-003"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fibroblast growth factor 21 (FGF21) is a regulator of glucose homeostasis, and is suggested to have protective effect on diabetic nephropathy. Its impact on non-diabetic kidney disease is unclear. To investigate the impact of FGF21 on contrast-induced nephropathy (CIN), 531 subjects underwent elective coronary angiography (CAG) were enrolled. Baseline creatinine and FGF21 were obtained before CAG. Patients were grouped into tertiles according to their FGF21 concentration. Creatinine was obtained 48\u2009hours after CAG, and every 6 months in the follow-up period. Renal function decline was defined as &gt;30% reduction of eGFR from baseline. All subjects were followed up till December 2016, or till the occurrence of major adverse cardiovascular events (MACE). Patients with higher FGF21 concentration were older, had higher incidence of hypertension, diabetes, chronic kidney disease, and heart failure. Thirty-four cases of CIN and 111 cases of renal function decline were identified during mean follow-up of 2.3\u2009\u00b1\u20091.3 years. Circulating FGF21 level was independently associated with CIN (aOR: 4.66, 95% CI: 1.29\u201316.86,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.019) and renal function decline (aHR: 7.98, 95% CI: 4.07\u201315.66,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) whether diabetes was present or not. In conclusion, circulating FGF21 level is independently associated with the incidence of CIN and subsequent kidney injury in patients undergoing CAG.\n                  <\/jats:p>","DOI":"10.1038\/s41598-018-30744-8","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T05:30:04Z","timestamp":1534224604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Circulating Fibroblast Growth Factor 21 is Associated with Subsequent Renal Injury Events in Patients Undergoing Coronary Angiography"],"prefix":"10.1038","volume":"8","author":[{"given":"Cheng-Hsueh","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruey-Hsing","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Sung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Hsun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Bang","family":"Leu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Chou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaw-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shing-Jong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"30744_CR1","first-page":"254","volume":"47","author":"MR Rudnick","year":"1995","unstructured":"Rudnick, M. R. et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. The iohexol cooperative study. Kidney Int. 47, 254\u2013261 (1995).","journal-title":"The iohexol cooperative study. Kidney Int."},{"key":"30744_CR2","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1161\/CIRCULATIONAHA.111.085290","volume":"125","author":"M Maioli","year":"2012","unstructured":"Maioli, M. et al. Persistent renal damage after contrast-induced acute kidney injury: Incidence, evolution, risk factors, and prognosis. Circulation. 125, 3099\u20133107 (2012).","journal-title":"Circulation."},{"key":"30744_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0002-9343(97)00150-2","volume":"103","author":"PA McCullough","year":"1997","unstructured":"McCullough, P. A. et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med. 103, 368\u2013375 (1997).","journal-title":"Am J Med."},{"key":"30744_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cjca.2015.05.013","volume":"32","author":"L Azzalini","year":"2016","unstructured":"Azzalini, L. et al. Contrast-induced nephropathy: From pathophysiology to preventive strategies. Can J Cardiol. 32, 247\u2013255 (2016).","journal-title":"Can J Cardiol."},{"key":"30744_CR5","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker, S. et al. 2014 esc\/eacts guidelines on myocardial revascularization: The task force on myocardial revascularization of the european society of cardiology (esc) and the european association for cardio-thoracic surgery (eacts)developed with the special contribution of the european association of percutaneous cardiovascular interventions (eapci). Eur Heart J. 35, 2541\u20132619 (2014).","journal-title":"Eur Heart J."},{"key":"30744_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.drudis.2013.10.021","volume":"19","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Fibroblast growth factor 21, the endocrine fgf pathway and novel treatments for metabolic syndrome. Drug Discov Today. 19, 579\u2013589 (2014).","journal-title":"Drug Discov Today."},{"key":"30744_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4093\/dmj.2014.38.4.245","volume":"38","author":"KH Kim","year":"2014","unstructured":"Kim, K. H. et al. Fgf21 as a stress hormone: The roles of fgf21 in stress adaptation and the treatment of metabolic diseases. Diabetes Metab J. 38, 245\u2013251 (2014).","journal-title":"Diabetes Metab J."},{"key":"30744_CR8","doi-asserted-by":"publisher","first-page":"e82275","DOI":"10.1371\/journal.pone.0082275","volume":"8","author":"C Zhang","year":"2013","unstructured":"Zhang, C. et al. Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. PloS One. 8, e82275 (2013).","journal-title":"PloS One."},{"key":"30744_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1523-1755.2005.00377.x","volume":"68","author":"PB Persson","year":"2005","unstructured":"Persson, P. B. et al. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 68, 14\u201322 (2005).","journal-title":"Kidney Int."},{"key":"30744_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/ki.1992.206","volume":"41","author":"LS Weisberg","year":"1992","unstructured":"Weisberg, L. S. et al. Radiocontrast-induced nephropathy in humans: Role of renal vasoconstriction. Kidney Int. 41, 1408\u20131415 (1992).","journal-title":"Kidney Int."},{"key":"30744_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1148\/radiol.2353040726","volume":"235","author":"MC Heinrich","year":"2005","unstructured":"Heinrich, M. C. et al. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology. 235, 843\u2013849 (2005).","journal-title":"Radiology."},{"key":"30744_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1161\/CIRCULATIONAHA.110.970160","volume":"123","author":"MT James","year":"2011","unstructured":"James, M. T. et al. Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease I. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation. 123, 409\u2013416 (2011).","journal-title":"Circulation."},{"key":"30744_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich, G. et al. The effects ofly2405319, an fgf21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333\u2013340 (2013).","journal-title":"Cell Metab."},{"key":"30744_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cmet.2008.06.014","volume":"8","author":"C Galman","year":"2008","unstructured":"Galman, C. et al. The circulating metabolic regulator fgf21 is induced by prolonged fasting and pparalpha activation in man. Cell Metab. 8, 169\u2013174 (2008).","journal-title":"Cell Metab."},{"key":"30744_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1042\/BJ20111748","volume":"443","author":"AL De Sousa-Coelho","year":"2012","unstructured":"De Sousa-Coelho, A. L. et al. Activating transcription factor 4-dependent induction of fgf21 during amino acid deprivation. Biochem J. 443, 165\u2013171 (2012).","journal-title":"Biochem J."},{"key":"30744_CR16","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang, X. et al. Serum fgf21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 57, 1246\u20131253 (2008).","journal-title":"Diabetes."},{"key":"30744_CR17","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2337\/dc09-0684","volume":"32","author":"AO Chavez","year":"2009","unstructured":"Chavez, A. O. et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 32, 1542\u20131546 (2009).","journal-title":"Diabetes Care."},{"key":"30744_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","volume":"53","author":"H Li","year":"2010","unstructured":"Li, H. et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 53, 934\u2013940 (2010).","journal-title":"J Hepatol."},{"key":"30744_CR19","doi-asserted-by":"publisher","first-page":"e15534","DOI":"10.1371\/journal.pone.0015534","volume":"5","author":"Z Lin","year":"2010","unstructured":"Lin, Z. et al. Serum levels of fgf-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PloS One. 5, e15534 (2010).","journal-title":"PloS One."},{"key":"30744_CR20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.metabol.2011.10.012","volume":"61","author":"WX Jian","year":"2012","unstructured":"Jian, W. X. et al. Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism. 61, 853\u2013859 (2012).","journal-title":"Metabolism."},{"key":"30744_CR21","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1210\/jc.2014-3465","volume":"100","author":"CH Lee","year":"2015","unstructured":"Lee, C. H. et al. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metab. 100, 1368\u20131375 (2015).","journal-title":"J Clin Endocrinol Metab."},{"key":"30744_CR22","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1210\/en.2012-2276","volume":"154","author":"HW Kim","year":"2013","unstructured":"Kim, H. W. et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db\/db mice. Endocrinology. 154, 3366\u20133376 (2013).","journal-title":"Endocrinology."},{"key":"30744_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2337\/dc08-1054","volume":"32","author":"S Stein","year":"2009","unstructured":"Stein, S. et al. Serum levels of the adipokine fgf21 depend on renal function. Diabetes Care. 32, 126\u2013128 (2009).","journal-title":"Diabetes Care."},{"key":"30744_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/cen.12380","volume":"80","author":"J Hindricks","year":"2014","unstructured":"Hindricks, J. et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol. 80, 918\u2013924 (2014).","journal-title":"Clin Endocrinol."},{"key":"30744_CR25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1532-5415.2011.03879.x","volume":"60","author":"C Crasto","year":"2012","unstructured":"Crasto, C. et al. Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults. J Am Geriatr Soc. 60, 792\u2013793 (2012).","journal-title":"J Am Geriatr Soc."},{"key":"30744_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2016.12.024","volume":"11","author":"MA Gomez-Samano","year":"2017","unstructured":"Gomez-Samano, M. A. et al. Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol. 11, 335\u2013341 (2017).","journal-title":"Redox Biol."},{"key":"30744_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.intimp.2016.05.026","volume":"38","author":"Y Yu","year":"2016","unstructured":"Yu, Y. et al. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-\u03baB signaling pathway. Int Immunopharmacol. 38, 144\u2013152 (2016).","journal-title":"Int Immunopharmacol."},{"key":"30744_CR28","doi-asserted-by":"publisher","first-page":"E1319","DOI":"10.1210\/jc.2015-2700","volume":"100","author":"SE Thiessen","year":"2015","unstructured":"Thiessen, S. E. et al. Fgf21 response to critical illness: Effect of blood glucose control and relation with cellular stress and survival. J Clin Endocrinol Metab. 100, E1319\u20131327 (2015).","journal-title":"J Clin Endocrinol Metab."},{"key":"30744_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 150, 604\u2013612 (2009).","journal-title":"Ann Intern Med."},{"key":"30744_CR30","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1210\/en.2017-03150","volume":"159","author":"AL Mayer","year":"2018","unstructured":"Mayer, A. L. et al. Enhanced Hepatic PPAR\u03b1 Activity Links GLUT8 Deficiency to Augmented Peripheral Fasting Responses in Male Mice. Endocrinology. 159, 2110\u20132126 (2018).","journal-title":"Endocrinology."},{"key":"30744_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep33953","volume":"6","author":"RH Chou","year":"2016","unstructured":"Chou, R. H. et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 6, 33953 (2016).","journal-title":"Sci Rep."},{"key":"30744_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jacc.2007.12.035","volume":"51","author":"PA McCullough","year":"2008","unstructured":"McCullough, P. A. Contrast-induced acute kidney injury. J Am Coll Cardiol. 51, 1419\u20131428 (2008).","journal-title":"J Am Coll Cardiol."},{"key":"30744_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jfma.2015.12.008","volume":"115","author":"RH Chou","year":"2016","unstructured":"Chou, R. H. et al. Chads2 score predicts risk of contrast-induced nephropathy in stable coronary artery disease patients undergoing percutaneous coronary interventions. J Formos Med Assoc. 115, 501\u2013509 (2016).","journal-title":"J Formos Med Assoc."},{"key":"30744_CR34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey, A. S. et al. Gfr decline as an end point for clinical trials in ckd: A scientific workshop sponsored by the national kidney foundation and the us food and drug administration. Am J Kidney Dis. 64, 821\u2013835 (2014).","journal-title":"Am J Kidney Dis."},{"key":"30744_CR35","first-page":"1393","volume":"44","author":"R Mehran","year":"2004","unstructured":"Mehran, R. et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol. 44, 1393\u20131399 (2004).","journal-title":"J Am Coll Cardiol."},{"key":"30744_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R. et al. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 44, 837\u2013845 (1988).","journal-title":"Biometrics."},{"key":"30744_CR37","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation. 97, 1837\u20131847 (1998).","journal-title":"Circulation."}],"updated-by":[{"DOI":"10.1038\/s41598-018-35360-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30744-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:40:50Z","timestamp":1671594050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30744-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["30744"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-30744-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12425"}}